Best Oncology Companies in Switzerland
The 117 best Oncology companies in Switzerland in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: ADC Therapeutics.
Switzerland's oncology sector is where $3.1 billion in disclosed funding across 117 tracked companies tells you something real is building. This directory ranks the best Oncology companies in Switzerland by that funding base and recent momentum, and the numbers reward a close look. Alentis Therapeutics leads at $184M raised, with Numab close behind at $150M. Those two alone account for more than a tenth of the entire pool. Global context matters here too: the oncology market sits at roughly $250.9B in 2025 and is forecast to more than double by 2034, driven by precision medicine expansion and rising cancer incidence. Cost-containment policies are the friction point every Swiss biotech is quietly pricing in.
So what's actually moving the needle right now? Hot themes this quarter include cancer biomarkers and angiogenesis inhibitors, and AI's expanding role in oncology genetics is reshaping how early-stage companies here frame their pipelines. I'd also flag the cross-border deal activity: Zydus's push into U.S. oncology signals that acquirers are actively hunting. Venture Kick and BioMedPartners are the most active backers you'll see across this list. No unicorns yet, but the funding density suggests that won't hold.
- Pharma 50 Deep Dive: Oncology leads with $110B in sales; GLP-1s contin
- Oncology Market Is Encouraged to Reach USD 646.33 Billion by 2032
Our analysis of 50 Oncology companies
$16.3b in tracked funding; 86% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Oncology companies in Switzerland
| # | Company | Disclosed funding | Last round | Stage | Employees | Founder | Market signals (1y) | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | ADC Therapeutics Developer of antibody-drug conjugates for the treatment of cancer indications | $641M | 61 mo ago | Public | 50 | Stephen Freke Co-Founder & Director | 7 signals ▲40% Earnings · Announcements | 526 patents Patents concentrated in health & consumer products | 3 awards |
| 2 | Bright Peak Therapeutics Developer of small molecule-based therapeutic solutions for the treatment of cancer and autoimmune disease | $232M | 25 mo ago | Series C | 57 | Jeffrey Bode Co-Founder | — | 91 patents Engineered cytokine immunocytokines for targeted immune activation in oncology | — |
| 3 | Alentis Therapeutics Developer of therapies for treating fibrosis, cirrhosis, and liver cancer | $184M | 19 mo ago | Series D | 38 | Thomas Baumert Founder & Board Member | 5 signals ▲400% Leadership | 35 patents Bispecific anti‑Claudin‑1/EGFR antibodies for cancer, liver disease and fibrosis therapy | — |
| 4 | Anaveon Developer of immunotherapies for treating cancers | $157M | 54 mo ago | Series B | 30 | — | — | 13 patents Engineered cytokine fusion proteins and PD‑1 antibody domains for immuno‑oncology therapeutics. | — |
| 5 | Nouscom Developer of viral-vector-based vaccines for the treatment of cancer | $152M | 27 mo ago | Series C | 37 | — | — | 129 patents Personalized and universal cancer vaccines using neoantigens and viral vector immunotherapies | — |
| 6 | Numab Developer of multispecific antibody therapeutics for inflammation and cancer | $150M | 17 mo ago | Series C | 78 | David Urech CEO | — | 38 patents Engineering bispecific and multispecific antibody formats for therapeutic targeting. | — |
| 7 | Anokion Developer of therapeutic proteins to treat autoimmune and allergic diseases | $112M | 44 mo ago | Deadpooled | 30 | — | — | 65 patents Patents concentrated in health & consumer products | — |
| 8 | iOnctura Developer of pharmaceuticals to treat cancer | $112M | 24 mo ago | Series B | 20 | Lars van der Veen Founder & CTO | 3 signals ▲50% Leadership | 39 patents Patents concentrated in health & consumer products | — |
| 9 | ImmunOs Therapeutics Developer of immunotherapies for the treatment of cancer and autoimmune diseases | $102M | 21 mo ago | Series C | 31 | Christoph Renner Co-Founder & CMO | — | 33 patents Engineered HLA fusion proteins targeting CD47‑SIRPA checkpoint for cancer immunotherapy | — |
| 10 | Nuclidium Developer of radiopharmaceuticals for the treatment of cancer | $99M | 0 mo ago | Series B | 8 | Leila Jaafar Founder & CEO | — | 41 patents Targeted radiopharmaceuticals for FAP and integrin imaging/therapy using high-purity radionuclides | — |
| 11 | Memo Therapeutics Developer of antibodies for treating infectious diseases and cancer | $97M | 25 mo ago | Series C | 21 | — | — | 52 patents Therapeutic antibodies targeting BK virus and SIGLEC‑9, plus immunoreceptor gene recovery | 1 partnership |
| 12 | CDR-Life Developer of antibody therapeutics for the treatment of cancer | $76M | 50 mo ago | Series A | 58 | Christian Leisner CEO & Co-Founder | — | 63 patents Therapeutic antibodies and bispecific T‑cell engagers targeting cancer peptides and ocular diseases | 1 launch |
| 13 | NBE-Therapeutics Developer of antibody-drug conjugates for cancer | $66M | 77 mo ago | Acquired | 21 | — | — | 154 patents Site-specific antibody‑drug conjugate technologies using anthracycline payloads | 1 job opening |
| 14 | PIQUR Developer of anti-cancer drugs based on lipid kinase (PI3K) and mTOR inhibition | $60M | 131 mo ago | Series A | 9 | — | — | — | — |
| 15 | Molecular Partners Developer of therapeutic solutions for treating multiple diseases | $60M | 71 mo ago | Public | 175 | Patrick Amstutz CEO | 5 signals ▼29% Earnings | 394 patents Engineered ankyrin repeat protein therapeutics targeting immune checkpoints and tumor antigens | — |
| 16 | TOLREMO therapeutics Developing anti-cancer small molecules targeting novel drug resistance pathways | $56M | 33 mo ago | Series A | 16 | Karl-Heinz Altmann Co-Founder | — | 71 patents Patents concentrated in health & consumer products | 1 job opening |
| 17 | Anergis Developer of vaccines against birch pollen allergy, ragweed and dust mites allergy | $49M | 122 mo ago | Deadpooled | 11 | — | — | 60 patents Patents concentrated in health & consumer products | — |
| 18 | Cellestia Developer of small molecule cancer therapeutics targeting NOTCH pathway | $48M | 58 mo ago | Series C | 19 | — | — | — | — |
| 19 | T3 Pharma Developer of novel and innovative medicines to treat cancer | $43M | 71 mo ago | Acquired | 18 | — | — | 245 patents Novel small‑molecule immunomodulators and anti‑angiogenic agents for inflammatory and oncologic therapies | — |
| 20 | Delenex Antibody therapeutics for oncology and dermatological inflammatory diseases | $41M | 151 mo ago | Acquired | — | Eric de La Fortelle ex-CEO | — | — | — |
| 21 | Polyphor Developer of macrocycle drugs for infections, breast cancer, cystic fibrosis, and others | $40M | 66 mo ago | Public | 119 | Daniel Obrecht Co-Founder | — | 599 patents Peptide peptidomimetic elastase inhibitors and CXCR4‑targeted cancer combination therapeutics | — |
| 22 | Opna Bio Developer of therapeutics for the treatment of cancer | $38M | 43 mo ago | Series A | 17 | Douglas Hanahan Co-Founder | — | 42 patents Patents concentrated in chemistry & materials | — |
| 23 | 4D Lifetec Developer of a diagnostic test for genotoxicity to diagnose multiple cancers | $37M | 32 mo ago | Series C | 6 | — | — | 28 patents Cancer screening via single‑cell electrophoresis detecting DNA‑damage biomarkers | — |
| 24 | Amal Therapeutics Developer of therapeutic vaccine for cancer | $37M | 91 mo ago | Acquired | 27 | Laetitia Devy-Dimanche Chief Executive Officer | — | 101 patents Intracellular delivery of cell‑penetrating peptide complexes for cancer immunotherapy | — |
| 25 | Calypso Biotech Developer of antibody-based therapeutics for the treatment of gastrointestinal diseases | $36M | 57 mo ago | Acquired | 12 | — | — | 29 patents Therapeutic antibodies targeting IL‑15 cytokine and MMP‑9 protease for inflammatory disease treatment | — |
| 26 | Vector BioPharma Developer of gene delivery platform to treat various disease conditions | $30M | 46 mo ago | Deadpooled | 39 | Lorenz Mayr Co-Founder | — | 7 patents Targeted adenoviral gene‑delivery platforms for immune‑cell therapies and vector production | — |
| 27 | SamanTree Medical Developer of digital microscopy system for high-resolution imaging of tissue | $28M | 4 mo ago | Series C | 25 | Etienne Shaffer CTO & ex-Co-Founder | — | 61 patents Fluorescence microscopy reagents and motion‑reduced confocal imaging systems | 2 partnerships |
| 28 | Aurealis Therapeutics Developer of cell and gene therapies for chronic wounds and cancer | $22M | 19 mo ago | Series B | 17 | — | — | 10 patents Inducible bacterial expression platforms for therapeutic protein production | 1 job opening |
| 29 | Volumina Medical Developer of scaffold for the natural repair of 3D soft tissues | $21M | 26 mo ago | Series A | 9 | Philippe Renaud Co-Founder | — | 11 patents Patents concentrated in health & consumer products | 1 job opening |
| 30 | 4-Antibody Antibody discovery and optimization platform for drug development | $21M | 233 mo ago | Acqui-Hired | 42 | — | — | 8 patents Antibody and binding protein discovery/engineering using nucleic acid sequencing and modified lymphocytes | — |
| 31 | Novigenix Developer of technology for cancer precision medicine | $20M | 14 mo ago | Series B | 28 | — | — | 20 patents Predictive biomarkers and assays for cancer immunotherapy response and colorectal neoplasia detection | — |
| 32 | Lymphatica Medtech Developer of medical devices for the treatment of lymphatic diseases | $20M | 20 mo ago | Series B | 8 | Marco Pisano Co-Founder & CEO | — | 4 patents Patents concentrated in health & consumer products | — |
| 33 | TargImmune Therapeutics Developer of drugs for treating cancer | $19M | 59 mo ago | Acquired | 21 | Esteban Villar CEO | — | 99 patents Polymer‑based targeted nucleic‑acid delivery systems for cancer immunotherapy | — |
| 34 | Virometix Vaccines and immunotherapeutic drugs for the prevention and treatment of infectious diseases (both bacterial… | $19M | 7 mo ago | Series C | 15 | Anna Sumeray CEO | — | 41 patents Vaccine antigen design and peptide‑based immunogens for pneumococcal and RSV protection | — |
| 35 | ProteoMediX Developer of next-generation blood test for prostate cancer | $18M | 57 mo ago | Acquired | 11 | — | — | 16 patents Clinical proteomics diagnostics: protein detection in human samples combined with MRI data | — |
| 36 | Engimmune Therapeutics Developer of T-cell receptor-based therapeutics for cancer and autoimmune diseases | $16M | 49 mo ago | Seed | 25 | Sai Reddy Co-Founder | — | — | — |
| 37 | Inthera Biosciences Developer of therapeutics to treat cancer | $15M | 108 mo ago | Series A | 4 | — | — | — | — |
| 38 | Sellas Life Sciences Developer of therapeutics for the treatment of cancer | $14M | 70 mo ago | Public | 17 | — | — | — | — |
| 39 | Aurealis Pharma Developer of treatments for inflammatory diseases | $13M | 60 mo ago | Series A | — | Thomas Wirth Co-Founder & Chairman | — | — | — |
| 40 | FoRx Therapeutics Developer of compounds for treating cancer | $11M | 6 mo ago | Series A | 22 | Sotirios Sotiriou Co-Founder | — | 35 patents Small-molecule inhibitors of PARG and WRN enzymes for cancer therapeutics | — |
| 41 | NovaGo Therapeutics Company developing human derived antibodies for cerebral stroke and spinal cord injury | $10M | 87 mo ago | Series A | 5 | Martin Schwab Founder & President | — | 14 patents Therapeutic anti‑Nogo‑A antibodies for CNS injury and neuro‑degenerative disease treatment | — |
| 42 | Artidis Provider of nanotechnology tool for cancer diagnosis | $9M | 78 mo ago | Seed | 4 | Marija Plodinec Co-Founder & Chief Executive Officer | — | 21 patents Nanomechanical tissue analysis via atomic force microscopy for cancer diagnostic and treatment prediction | — |
| 43 | Navignostics Developer of personalized diagnostics for cancer patients | $8M | 45 mo ago | Seed | 8 | Jana Fischer Co-Founder | — | — | — |
| 44 | MaxiVAX Developing immunotherapies for treating cancer | $5M | 47 mo ago | Series B | 8 | Bernard Mach Co-Founder & Executive Chairman | — | 35 patents Implantable drug‑delivery capsules and immortalized myoblast cell platforms for therapeutic protein production | — |
| 45 | Invasight Developer of therapeutic agents to inhibit cancer cell prognosis | $5M | 48 mo ago | Seed | 6 | Karthiga Kumar Co-Founder | — | — | — |
| 46 | PreComb Provides functional cancer profiling using biomarker analysis | $4M | 17 mo ago | Series A | 11 | Jens Kelm Co-Founder | — | — | — |
| 47 | Terapet Developer of integrated imaging solutions for proton therapy and nuclear medicine | $4M | 27 mo ago | Seed | 8 | Raymond Miralbell Co-Founder & CSO | — | 36 patents Patents concentrated in computing, sensing & instrumentation | — |
| 48 | Elthera Provider of precision medicine for oncology | $3M | 39 mo ago | Funding Raised | 5 | Gunther Spohn Co-Founder & CSO | — | 11 patents L1CAM-targeted therapeutic antibodies for hematological malignancies | — |
| 49 | Adiposs Developer of medical imaging equipment for the diagnosis of cachexia | $2M | 11 mo ago | Series A | 7 | Justyna Plewka Co-Founder & COO | — | 13 patents Medical imaging contrast agents and therapeutic emulsions for diagnostic and nutritional applications. | — |
| 50 | MPC Developer of new generation of small molecules for cancer and degenerative diseases | $2M | 31 mo ago | Seed | — | Augustin Bettignies Co-Founder & Co-CEO | — | — | — |
Top 12 Oncology companies in Switzerland
#1
Series B · Basel, Basel Stadt · founded 2017 · 8 employees$99Mraised▾
Developer of radiopharmaceuticals for the treatment of cancer. The company is developing copper-based therapeutics and companion diagnostics which include NuriPro for Prostate cancer, TraceNET for Neuroendocrine tumors (NET), and CuNeo for Colorectal, Gastric & lobular breast cancer.
- Jul 2025Series B$99M
#2
Series C · Lausanne, Vaud · founded 2014 · 25 employees$27.8Mraised▾
Developer of digital microscopy system for high-resolution imaging of tissue. The system allows rapid imaging of fresh tissue surfaces without slicing. It uses confocal microscopy for tissue visualization while preserving the specimen. The system includes a fluorescent stain and single-use device for imaging. Digital tools allow physicians to review images remotely and annotate areas of interest.
- Jan 2026Series C$23.7M
- Apr 2025Series B$6M
- Jul 2024Series B$14M
- Aug 2021Grant (prize money)$59K
#3
Series C · Zurich, Zurich · founded 2009 · 15 employees$18.9Mraised▾
Virometix is a privately held biotechnology company developing a new generation of vaccines and immunotherapeutic drugs for the prevention and treatment of infectious and chronic human diseases. Rational molecular design, chemical synthesis and Virometix's proprietary Synthetic Virus-Like Particle platform technology allow for the rapid production and optimization of vaccine candidates with superior properties in terms of safety, efficacy and stability. Virometix Vaccines is a spin-out company from the University of Zurich.
- Nov 2025Series C$15M
- Jul 2020Series B$8M
- Sep 2017Series A$1.3M
- May 2017Series A$5.1M
#4
Series A · Basel, Basel Stadt · founded 2019 · 22 employees$10.8Mraised▾
FORx Therapeutics develops compounds for treating cancer. The compounds work against targets involved in the repair of collapsed DNA replication forks. The company is developing small chemical inhibitors of the DNA repair pathways to specifically target cancer cells while sparing normal cells.
- Dec 2025Series A$50M
- Jun 2024Series A—
- Apr 2020Seed$10.8M
#5
Series C · Wadenswil, Zurich · founded 2011 · 78 employees$149.7Mraised▾
Developer of multispecific antibody therapeutics for inflammation and cancer. The company applies proprietary discovery and engineering platforms to generate antibody fragment-based candidates with tailored pharmacokinetic properties. Its pipeline includes first-in-class bispecific and multispecific drug candidates targeting inflammatory and oncological indications. The platform technology enables assembly of stable, highly potent antibody formats using modular building blocks. By leveraging scalable, reproducible engineering methods, the company accelerates therapeutic discovery and optimizes manufacturing characteristics.
- Jan 2025Series C$55M
- May 2021Series C$111M
- Mar 2020Series B$23.5M
- Dec 2019Series B$15.2M
#6
Series D · Basel, Basel Stadt · founded 2019 · 38 employees$184.3Mraised▾
Developer of therapies for treating fibrosis, cirrhosis, and liver cancer. They have developed a gene expression platform. Their drug candidates (monoclonal antibodies) target a cell surface protein, which is being investigated for liver disease and cancer. The products include ALE-F02, CLDN1 for Liver Fibrosis (F3/F4) and kidney fibrosis, and ALE-C04, CLDN1 for Hepatocellular Carcinoma (HCC), and Cholangiocarcinoma.
- Nov 2024Series D$181.4M
- Apr 2023Series C$105M
- Jun 2021Series B$67M
- Apr 2019Series A$12.3M
#7
Series C · Schlieren, Zurich · founded 2013 · 31 employees$102.5Mraised▾
Developer of immunotherapies for the treatment of cancer and autoimmune diseases. The company has an HLA-based pipeline that includes first-in-class immunotherapies for the treatment of cancer and autoimmune diseases. The Company´s lead product candidate, IOS-1002, is an HLA-based protein that blocks the activation of three different immunosuppressive receptors (also known as checkpoints) on innate and adaptive immune cells
- Sep 2024Series C$11M
- Jun 2022Series B$74M
- Dec 2019Series A$15.2M
- Oct 2018Series A—
#8
Series B · Epalinges, Vaud · founded 2014 · 28 employees$20Mraised▾
Developer of technology for cancer precision medicine. It offers an Immuno-transcriptomic platform combined with machine learning and predictive algorithms that enables the identification of disease-specific mRNA signatures of immune cells and the progression of the disease. Its lead product, Colox a molecular test that measures the immune system's reaction to colorectal cancer.
- Apr 2025Grant (prize money)$2M
- Nov 2022Series B$20M
- Jan 2020Grant (prize money)$1.1M
#9
Series C · Basel, Basel Stadt · founded 2017 · 57 employees$232Mraised▾
Developer of small molecule-based therapeutic solutions for the treatment of cancer and autoimmune disease. The company is involved in the development of cytokines by using Enhanced Design and Combine (EDC) platform for immuno-oncology indications.
- May 2024Series C$90M
- Mar 2021Series B$107M
- Jul 2020Series A$35M
#10
Series B · Basel, Basel Stadt · founded 2010 · 17 employees$22Mraised▾
Developer of cell and gene therapies for chronic wounds and cancer. The company focuses on creating therapies for unmet medical needs. Its multi-target cell and gene therapy platform addresses complex multi-factorial diseases. The company generates pre-clinical, clinical, and health-economic evidence.
- Nov 2024Series B$9M
- 2021Series A—
- Aug 2017Series A$5.8M
- Jan 2016Seed$3.3M
#11
Series B · Geneva, Geneva · founded 2017 · 20 employees$111.7Mraised▾
Developer of pharmaceuticals to treat cancer. The company is developing a pipeline of next-generation, precision molecules for oncology indications which include IOA-244 and IOA-359 for solid tumors, and hematological malignancies and IOA-289 for pancreatic cancer.
- Jun 2024Series B$85.9M
- Dec 2022Grant (prize money)$18.6M
- Nov 2022Series A$1.2M
- Sep 2022Conventional Debt$403.9K
#12
Series B · Lausanne, Vaud · founded 2015 · 8 employees$19.6Mraised▾
Developer of medical devices for the treatment of lymphatic diseases. The company offers "Lymph Drain" a catheter system implanted subcutaneously that intended to recirculate lymph inside the patient body, re-establishing the physiological fluid equilibrium.
- Oct 2024Series B$19.6M
- Jul 2022Grant (prize money)$51.1K
- Dec 2020Series A—
- Sep 2019Grant (prize money)$2M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Oncology coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.